Dizal receives a 600 million USD upfront payment from AstraZeneca under a licensing agreement
According to 36Kr, Dizal Medical announced that on July 14, 2026, it signed a licensing agreement with AstraZeneca granting global exclusive rights to develop and commercialize Shuwozhe, with the agreement taking effect on August 31, 2026, and the company receiving a 600 million USD upfront payment.
Key facts
- 01Dizal Medical signed a licensing agreement with AstraZeneca.
- 02The agreement grants global exclusive rights to develop and commercialize Shuwozhe.
- 03The agreement becomes effective on August 31, 2026.
- 04Dizal Medical received a 600 million USD upfront payment.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.
- 迪哲医药：公司收到阿斯利康6亿美元首付款 · 36氪